Explore

Trendline Trendline
ARK Invest Joins Cellares' $277 Million Series D to Advance Cell Therapy Manufacturing

ARK Invest Joins Cellares' $277 Million Series D to Advance Cell Therapy Manufacturing

ARK Invest Joins Cellares' $277 Million Series D to Advance Cell Therapy Manufacturing
Trendline Trendline
Biopharma Industry Prepares for Growth with Talent Strategies Webinar

Biopharma Industry Prepares for Growth with Talent Strategies Webinar

Biopharma Industry Prepares for Growth with Talent Strategies Webinar
Trendline Trendline
NewYorkBIO Advocates for Sustained Federal Support Amid Life Sciences Funding Uncertainty

NewYorkBIO Advocates for Sustained Federal Support Amid Life Sciences Funding Uncertainty

NewYorkBIO Advocates for Sustained Federal Support Amid Life Sciences Funding Uncertainty
Trendline Trendline
American Biotech Innovation Alliance Forms to Counter China's Advancements in Biotech

American Biotech Innovation Alliance Forms to Counter China's Advancements in Biotech

American Biotech Innovation Alliance Forms to Counter China's Advancements in Biotech
Trendline Trendline
FDA Approves New Maintenance Regimen for Eli Lilly's Eczema Drug Ebglyss, Offering Fewer Injections

FDA Approves New Maintenance Regimen for Eli Lilly's Eczema Drug Ebglyss, Offering Fewer Injections

FDA Approves New Maintenance Regimen for Eli Lilly's Eczema Drug Ebglyss, Offering Fewer Injections
Trendline Trendline
Life Science Trade Groups Urged to Support Industry Amid Federal Funding Uncertainty

Life Science Trade Groups Urged to Support Industry Amid Federal Funding Uncertainty

Life Science Trade Groups Urged to Support Industry Amid Federal Funding Uncertainty
Trendline Trendline
ARK Invest Joins Cellares' $277 Million Series D to Boost Cell Therapy Manufacturing

ARK Invest Joins Cellares' $277 Million Series D to Boost Cell Therapy Manufacturing

ARK Invest Joins Cellares' $277 Million Series D to Boost Cell Therapy Manufacturing
Trendline Trendline
N-Zyme Biomedical Initiates Phase 2 Trial for Pepsin Inhibitor in Reflux Disease

N-Zyme Biomedical Initiates Phase 2 Trial for Pepsin Inhibitor in Reflux Disease

N-Zyme Biomedical Initiates Phase 2 Trial for Pepsin Inhibitor in Reflux Disease
AP News AP News
Another sell-off for AI stocks drags Wall Street to its first back-to-back drop in weeks

Another sell-off for AI stocks drags Wall Street to its first back-to-back drop in weeks

Another sell-off for artificial-intelligence stocks dragged the U.S. market sharply lower
AP News AP News
More drops for tech stocks weigh on Wall Street

More drops for tech stocks weigh on Wall Street

Technology stocks are continuing to fall, putting the S&P 500 on track for its first back-to-back drop in three weeks
AP News AP News
Wall Street drifts after tech stocks keep swinging

Wall Street drifts after tech stocks keep swinging

The U.S. stock market is drifting in mixed trading as technology stocks keep swinging
Trendline Trendline
Kailera Therapeutics Advances Obesity Treatment with Record-Breaking IPO

Kailera Therapeutics Advances Obesity Treatment with Record-Breaking IPO

Kailera Therapeutics Advances Obesity Treatment with Record-Breaking IPO